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Recent years have seen an intensification of the datafication of reproduction, as 
increasingly large and automatically-generated data sets have come to play an 
instrumental role in the technological reproduction of human life. This development is 
evident at all stages of the reproductive process, whether in fertility apps for timing 
conception, genomic fertility testing, or the use of quantified visual data for embryo 
selection in IVF. The emergence of in silico reproduction alongside the familiar in 
vitro reproduction (e.g. IVF) follows from an understanding that an increasing number 
of aspects of reproduction can be “measured and monitored and treated as technical 
problems with technical solutions” (Kitchin, 2014, p. 181). It concerns not simply the 
use of data, which has long been part of technologised reproduction, but the attempted 
optimisation, automation, and standardisation of assisted reproductive processes in 
ways that rely on, generate and analyse large data sets with novel computational 
technologies, including predictive analytics and machine learning.  
One of the major changes in assisted reproduction today is the introduction of 
data technologies in the fertility lab with the aim of improving, automating and 
standardising previously-manual processes. Yet in spite of the growing scholarship on 
digital health, the datafication of assisted reproduction remains surprisingly 
understudied. As the so-called “data revolution” is transforming health care at large 
(Kitchin, 2014), it is pertinent to focus on assisted reproduction in particular because it 
is a relatively unregulated sector in which bioinnovations—including data-centric 
2 
 
ones—are introduced rapidly. Such innovations are relevant beyond their clinical 
(in)efficacy given the culturally-specific and politically-charged nature of reproductive 
processes and their reconceptualisation and reconfiguration in the face of new 
reproductive technologies (Franklin, 2013).  
One key influential reproductive data technology is time-lapse embryo 
imaging, a new data-intensive method of embryo selection used for deciding which 
embryos will be implanted in the womb in IVF. This embryo selection method 
displaces the embryologist’s manual appraisal of embryos under the microscope by 
continuously filming them in the incubator, quantifying the visual information and 
predicting their viability through algorithmic analyses. Hailed as the “greatest 
breakthrough in IVF in 25 years,” and criticised for its rapid introduction in the 
absence of “high level evidence of improved live birth rates, safety and cost 
effectiveness” (Armstrong et al., 2015a, 2015b; Harper et al., 2017; Walsh, 2013a), 
time-lapse embryo imaging is now widely available in fertility clinics worldwide and is 
changing the face of IVF.  
Major players in the fertility industry—including pharmaceutical giant Merck 
and biotechnology company Vitrolife—have heavily invested in time-lapse imaging 
and distribute systems to clinics across the globe. Although the HFEA, the UK’s 
fertility regulator, advises that there is “certainly not enough evidence to show that 
time-lapse imaging improves birth rates,” demand for this technology is growing 
(HFEA, 2018). For example, Vitrolife reported almost $100 million net global sales of 
time-lapse technologies in 2017, while the first quarter of 2018 has already secured 
$30 million net sales after the company received regulatory approval for its 
Embryoscope system in China, one of the world’s largest fertility markets 
(BusinessWire, 2011; Vitrolife, 2018a). As fertility clinics invest in time-lapse 
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imaging, more intended parents will be confronted with the question of whether to 
include this add-on in their IVF cycles—often at an increased cost.  
This article focuses on the new forms of knowledge and value production 
emerging with this data-driven time-lapse method of embryo selection and situates 
them in the techno-economic dynamics of an emerging global reproductive data 
infrastructure. It is written from the conviction that, in order to understand 
contemporary sociotechnological changes in human reproduction, we have to take into 
account the rationalities, power relations and global institutional configurations in the 
“reproductive-industrial complex” from which these bioinnovations emerge 
(Vertommen, 2017). In doing so, this project seeks to not simply present a case study 
of one particular reproductive technology, but approaches the rise of time-lapse 
embryo imaging as a lens onto the dynamics underlying the introduction of data-driven 
bioinnovations in (reproductive) health care more broadly.  
Adopting Vertommen’s genealogical method for the analysis of emerging bio-
economies, this article characterises the datafication of reproduction by analysing the 
genealogy of data-driven embryo selection in the contemporary global fertility sector 
(2017, pp. 286–7). Through a case study approach, which Feagin and colleagues define 
as an “in-depth, multifaceted investigation [that is] conducted in great detail and often 
relies on the use of several data sources,” I approach time-lapse selection as “an 
instance of [the] broader phenomenon” of datafied reproduction (1991, p. 1). 
Transposing Bal’s method of cultural analysis to this critical case study (2002), I 
analyse time-lapse embryo imaging by close reading key discursive objects that 
organise the marketisation of this technology—including patents, financial reports, 
direct-to-consumer advertisements and online platforms—in dialogue with influential 
conceptual frameworks in reproductive sociology and critical data studies.   
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This study builds on the work on the commercialisation and conceptualisation 
of prenatal life and fertility technologies in the field of reproductive sociology, notably 
by scholars such as Sarah Franklin (2013), Charis Thompson (2013) and Marcia Inhorn 
(2015). It provides an update on Deborah Spar’s analysis of the fertility market in The 
Baby Business (2006) by focusing on a newer, data-driven technology that allows for a 
characterisation of more recent changes in the IVF sector, including its ongoing 
expansion and consolidation, the rise of private equity investments, the significance of 
patenting and the commercialisation of reproductive data. These focus points align 
with a surge of scholarship in science and technology studies (STS) concerned with the 
relation between reproduction, cellular life and capital. Notably, the work on 
“biovalue” and “biocapital” by Sarah Franklin (2013), Catherine Waldby (2006),  Cori 
Hayden (2003) and Sunder Rajan (2006) analyses the transformation of biological 
substance into “generative forms of capital through which further commodities and 
value are created” (Murphy, 2017, p. 13). Drawing on Melinda Cooper’s 
characterisation of the self-generative capacities of stem cells and finance, it analyses 
the generative relations between embryogenesis, capital and biodata emerging with 
data-driven IVF (2008). It brings this work into dialogue with data studies by drawing 
on Van Dijck’s (2016), Hogle’s (2016) and Kitchin’s (2014) critical readings of the 
governance implications of “datafication.”  In doing so, it introduces in the field of 
reproductive sociology a focus on the “data revolution” in global IVF, which is 
fundamentally changing the mechanisms through which we can conceive, control and 
commercialise reproduction at large.  
In this way, I examine how the development and distribution of server-
connected embryo selection apparatuses is remaking assisted reproduction by 
introducing ‘emergent reproductive data infrastructures,’ ‘new reproductive 
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bioeconomies of data sharing’ and an ‘expansion of the scope of reproductive risk 
through predictive analytics’ by focusing on three aspects. Firstly, I propose 
reproductive data technologies such as time-lapse embryo imaging introduce an “in 
silico vision,” an algorithmic way of seeing through historical data sets that makes 
previous populations visible as the basis for future predictions. Secondly, I examine 
several controversies surrounding the patents and proprietary algorithms of embryo 
development and discuss how they reveal an ongoing renegotiation of the locus and 
ownership of expert knowledge and medical authority. Thirdly, by situating this 
technology in the institutional context of consolidating fertility, biotech and 
pharmaceutical companies, I address how time-lapse embryo imaging brings together 
self- and automated tracking, data infrastructures and social media in contemporary 
practices of technologically-assisted reproduction. In doing so, I argue that this 
datafied method of embryo selection may not just result in more or less “IVF success,” 
but also affects the conceptualisation and commercialisation of the assisted 
reproductive process and impacts the very coming into being of prenatal life.  
 
In Silico Vision 
Since its 2013 introduction in the UK, time-lapse embryo imaging has been promoted 
by major fertility clinics as an alternative, and superior, form of embryo selection. 
Whereas conventional selection relies on once-daily assessment of in vitro embryos 
under the microscope, time-lapse embryo imaging enables the embryos to remain 
undisturbed in the incubator and be photographed every 5-20 minutes. The visual data 
derived from these images is matched against predictive parameters to assess embryo 
quality. Emerging in the wake of an increasingly public visual interface with prenatal 
life, e.g. through imagery of IVF and fetal ultrasound, both of which have had a 
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profound impact on public and private imagination of the reproductive process, the 
resulting time-lapse embryo videos add yet another visual dimension to the encounter 
with early human life on screen (Duden, 1993; Franklin, 2013). For example, a 
downloadable embryo video is part of the IVF package at CARE, the UK’s largest 
fertility group, and Genea clinics live-stream images of developing embryos from the 
incubator to intended parents’ iPads. Yet beyond another mode of medical imaging that 
brings the embryo into view, these embryo videos introduce an “in silico vision,” an 
algorithmically-assisted way of seeing that makes the embryo legible, and its viability 
calculable, in new ways.  
 The advent of routine time-lapse imaging in the fertility clinic reconfigures the 
visual recognition of embryonic developmental stages. Rather than requiring manual 
observation, automated tracking algorithms record a number of visual aspects of 
development (e.g. cell division or cell quantity). In this process, a multiplicity of 
parameters recording specific visual aspects of the cells may be combined to ascribe a 
unique quantified value to each embryo (Merck, 2015). In turn, the time-lapse system 
matches the resulting visual data against historical data about previous cohorts of 
embryos to give a prediction of embryo viability. The viability outcomes are 
automatically layered onto the embryo videos with numerical scores, colours or 
superimposed words (‘high’ or ‘low’). Data analysis thus plays a key role in watching 
embryos in time-lapse embryo imaging as a means of not only making them visible, 
but rendering their viability legible, calculable and manageable.  
The move from daily examinations under the microscope to time-lapse embryo 
imaging then introduces a data-assisted way of seeing, or “in silico vision” in the 
embryological work flow. Now touching the screen instead of the petri dish, time-lapse 
embryo imaging allows embryologists to observe, record and compare cellular 
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behaviours that occurred in the petri dish in their absence—both in the incubated 
embryo cohort and those historical populations that preceded them. Tracking 
algorithms can record key developmental markers and provide suggestions for manual 
annotation (Vitrolife, 2015a). They likewise detect activities “beyond what the human 
eye is capable of measuring” by recording, for example, changes in the embryo’s 
textural granularity (Merck, 2015). In each of these ways, the introduction of in silico 
vision into the IVF lab presents an alternative mode of “authorised seeing” alongside 
the embryologist’s medical gaze through the microscope (Foucault, 1973; Jasanoff, 
2017).1  
With in silico vision, ‘assisted seeing’ through data correlations integrates 
calculation and observation with the aim of detecting regularity in temporally and 
spatially disperse embryo cohorts. This approach entails an epistemological shift in 
knowledge production about embryos, which is becoming a new standard as the 
popularity of these time-lapse systems grows.2 The marketing of time-lapse imaging 
positions in silico vision as a superior method of noninvasive embryo observation that 
allows for “a more objective analysis” (Vitrolife, 2018b). Although the epistemic 
fallacies underlying such claims to observational objectivity have been demonstrated,3 
I here follow Sheila Jasanoff’s approach of not attempting an “inquiry into the validity 
of particular data claims,” but exploring “how power works in rerepresenting things 
that happen in the world in the form of data points” (2017, p. 2). The claim to a “more 
objective analysis” is in line with what Jasanoff calls a “view from nowhere”—in 
                                                             
1 For a discussion of the medical gaze in relation to the prenatal imagery produced in time-lapse embryo 
imaging, see Van de Wiel (2017, 2018).   
2 Time-lapse embryo imaging is widely used in scientific studies in developmental biology. The tripling 
of citations on time-lapse embryo imaging from 447 to 1358 between 2013-2017 gives an indication of 
the impact of this technology on the field. Citation report generated at Thomson Reuter’s Web of Science 
“((time-lapse OR “time lapse”) AND (IVF OR ICSI OR “embryo selection”)).”  
3 see e.g. Fox Keller (1996). 
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contrast with views from everywhere and somewhere—as the ideal-type of a 
“disinterested purity of science.” This regime of seeing aligns with the problematic 
notion that “data” can “sanitize the world of observation,” erasing from view the 
observational standpoints and associated political choices underlying the compilation 
of authoritative information (Jasanoff, 2017, p. 12).   
However, as manual observation and assessment is supplemented by automated 
and datafied methods, there is not an erasure, but in fact a multiplication of 
observational standpoints as the embryologist ceases to be the sole observer and 
decision-maker in embryo selection. In silico vision denotes a more networked model 
of knowledge production that creates new forms of dependency in attaining “more 
objective” visions of prenatal life that are enmeshed with attendant data-centric forms 
of commodification. Essential components of in silico vision—the system itself, its 
interfaces, the data sets it generates and the algorithms with which they are analysed—
may now be owned by corporate actors, thereby positioning embryo selection as a 
significant nexus of power relations and capital flows in contemporary IVF.  
This paper examines the power relations at work in the establishment of in 
silico vision and the widespread introduction of data-driven embryo selection, as a 
particular organisation between those that produce, analyse and claim ownership of 
embryo data is built into the very means of seeing prenatal life. These concerns are 
vividly articulated through the controversies surrounding the patenting of data-driven 
embryo selection systems. 
 
Patenting Data-driven Embryo Selection 
 
The patenting of time-lapse imaging systems brought embryo development into the 
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realm of private property and thereby provoked controversy in the scientific and 
bioethics community. Because these patents include temporal parameters of embryo 
development, they provoked discussions about the patentability of natural phenomena. 
This section addresses the institutional and regulatory contexts from which the 
patenting of embryonic development emerges and their significance in rendering 
embryo development generative and valuable in new ways. It thereby highlights how 
the datafication transition in IVF raises fundamental questions about the 
conceptualisation and commercialisation of prenatal life as data-driven embryo 
selection becomes a means for creating new forms of capital accumulation. 
Between 2011 and 2013, both US and European patent offices issued patents 
covering the timing of cellular development as “predictive parameters” in embryo 
selection to Stanford University, with exclusive licensing to Auxogyn (now Progyny), 
the company that produced the Eeva test. The patents describe the association of “good 
developmental competence” with cellular temporal markers, such as a “duration of first 
cytokinesis […] between 0 and 30 minutes” and a “time interval […] between the 
resolution of cytokinesis 1 and the onset of cytokinesis 2 [of] 8-15 hours” (Baer et al., 
2011; Wong et al., 2013, 2012). Rather than only describing the technicalities of the 
embryo selection method, the patents thus also include the temporal specifics of 
embryo development as part of the patented intellectual property.  
Consequently, the question arose to what extent the timing of embryo 
development is a natural phenomenon, and therefore unpatentable, or an essential part 
of a new, patentable invention. Jacques Cohen, chief Editor of Reproductive 
BioMedicine Online, led a scholarly response to the Auxogyn patents and wrote a plea 
against “patenting time and other natural phenomena” in this journal:  
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Claiming cell cycle timing or duration as an invention that merits a patent would 
strike most students of developmental biology as an unlikely proposition but 
researchers at Stanford University have successfully done exactly that! The first 
three cell cycles in the human embryo developing in vitro are now owned by a 
corporation. (Cohen, 2013a, p. 109) 
 
He argues that “the length of the cell cycle is not an invention and its key role in 
development is not a new observation; it is an indisputable and well-known fact of 
nature” that has been described since the late-19th century. A precedent of patenting 
temporal phenomena, he claims, will have long-term problematic effects (2013a, p. 
109). In response, Stanford professor and inventor of the patent Renee Reijo Pera 
claimed that the patents cover the “assays intended to distinguish optimal [and 
suboptimal] embryos for transfer in IVF” and therefore entail a method rather than a 
natural phenomenon (2013).  
 In the ensuing riposte between Reijo Pera and Cohen, the former argues that the 
“diagnosis of embryo viability” does not address a “naturally occurring phenomenon” 
because there is “no need to distinguish quality amongst as many as 5-10 embryos (or 
even more) in natural conception; and in nature women simply do not conceive outside 
of the body” (2013, p. 113). Cohen responds that no studies have supported the 
premise that in vivo and in vitro cell cycles are fundamentally different processes; in 
fact it is their close resemblance that has resulted in the birth of over 5 million children 
from IVF. “Arguing that those processes were somehow not natural (and therefore 
patentable),” he suggests, “may instigate an entirely different discussion, not unlike 
those that engaged the opponents of IVF in its early days” (2013b, p. 115).  
The uncertainty surrounding the patentability of embryo development in the 
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context of time-lapse embryo imaging is another iteration of an ongoing renegotiation 
of legal ownership of human biological substances, and the data derived from them. In 
Bioinformation (2017), Bronwyn Parry and Beth Greenhough describe the difficulties 
of differentiating between ‘discoveries’ from ‘inventions’ in the context of 
biotechnologically reworked material, such as isolated DNA or immortalised cell lines. 
A series of legal rulings have determined that intellectual property rights to human 
biologicals can be claimed even if they are derived from human bodies, “because 
bringing them into the world was deemed an act of manufacture or invention, not just 
discovery” and the patents would recompense corporations for their expended labour 
(2017, p. 74).  
Yet it is important to recognise that in the case of time-lapse embryo imaging, 
the legal establishment of embryo development as patentable property occurs in 
response to purportedly “non-invasive” data-driven technologies. Time-lapse embryo 
imaging does not isolate or reconfigure the embryo in any way that is directly 
instrumentalised—as is the case for previously patented synthesised DNA or 
immortalised stem cell lines. Rather, it introduces new ways of extracting and 
analysing data from embryos and thereby repositions certain temporal parameters of 
embryo development as instruments for selection. It is, then, its manifestation in time 
as potential data points that can be instrumentalised in algorithm development and 
algorithmic analysis, that de-naturalises and re-technologises the embryo and its 
divisions. We may consider how the broader trend of datafication in health care, and 
the attendant patenting of data-driven health technologies, has re-ontologising effects, 
as it brings more previously-natural bodily phenomena in the realm of patentable 
inventions by virtue of their changing relationships to the expanding data sets and 
algorithmic instruments that record and analyse them.  
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  Returning to Pera-Reijo and Cohen’s discussion, the latter’s response does not 
address another, possibly more interesting aspect of Pera-Reijo’s justification of 
patenting the embryonic cell cycle, namely the political bioeconomies of embryo 
research and its clinical translations. Pera-Reijo explains the patent application 
followed the Republican 1996 Dickey-Wicker Amendment, which ceased US federal 
funding for human embryo research that resulted in the destruction of embryos, 
including those donated by IVF patients (2013).4 This restriction has resulted in 
scientists such as Pera-Reijo searching non-federal funding from for-profit partners, 
who would invest private capital in embryo research that could be translated into 
clinical benefits. She states that “without patents to protect the inventions made in this 
process , it would be nearly impossible to attract the investment finance needed to 
move a technology from the research and development phase, through clinical trials, 
through the regulatory process, and ultimately to commercialization” (Reijo Pera, 
2013, pp. 113–114). Conservative politics, informed by a widespread anti-abortion 
sentiment in the United States, thus played a key role in enlisting embryo research 
within a capitalist logic that requires a redefinition of embryo development as 
invention.   
Beyond the question of whether the patent is legitimate, what is at stake in 
these developments is the marketisation of evolving data and algorithms used for data-
driven embryo selection. While Cohen’s critique focused primarily on fixed temporal 
specificities of prenatal development, these and later time-lapse imaging patents 
describe temporal markers as more dynamic variables. For example, the same patent 
quoted above identifies “first cytokinesis, the second cleavage division and 
synchronicity of the second and third cleavage divisions” as parameters that  
                                                             
4 See Thompson (2013, pp.79-84) for a detailed discussion of the Dickey-Wicker Amendment.   
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can be measured automatically using the cell tracking algorithms and software 
previously described. The systems and methods described can be used to 
diagnose embryo outcome with key imaging predictors and can allow for the 
transfer of fewer embryos earlier in development. (Wong et al., 2013) 
 
Rather than fixing specific temporal values of these parameters, it is precisely a more 
dynamic model which combines ongoing automated tracking, data generation and 
algorithmic analysis that underlies a data-driven approach to “diagnos[ing] embryo 
outcome with key imaging predictors” (Wong et al., 2013). Reframed as diagnosis, this 
claim to predicting embryonic developmental potential is highly marketable in an IVF 
process that is characterised by uncertainty at each step of the way.  
Yet the key transformative aspect of this dynamic, data-driven embryo 
selection remains underdiscussed in the patenting debate; it follows less from questions 
on the nature of the embryo and more from time-lapse systems’ introduction of the 
data-generativity of embryos. Cellular generativity was at the heart of the patenting of 
stem cells, through which, Cooper argues, “the self-regeneration of life will coincide 
with the self-valorization of value” (2008, p. 147). The patenting of embryo 
development similarly points to a mode of cellular generativity that coincides with 
value production. The incubated embryo’s data-generativity propels not only clinical 
and scientific knowledge production, but also future life, as the data flows drawn from 
time-lapse embryos can be repurposed as tools for future selections. Once datafied as 
both tool and object of selection, the incubated developing embryo enters the realm of 
economic valuation neither, in the first instance, as an exchangeable commodity, nor as 
the materially and commercially self-accumulative stem cell line (Cooper, 2008, p. 
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148), but rather as a generative node in an ongoing automated process of data and 
algorithm production that anticipates and, potentially, enables future reproduction.5 In 
other words, what is at stake in the datafication of embryo development is the 
transmutation of enmeshed knowledge, reproductive and capital value emerging from 
the data-generativity of prenatal life.  
 
The Algorithmisation of Embryo Development  
 
At the heart of the valuation of data-driven embryo selection is the emergence of new 
software and algorithmic products, which produce new forms of datafied biocapital. As 
Pottage remarks, it has not only been patenting but “the adroit exploitation of 
trademarks and branding strategies,” that has spurred the growing popularity of 
particular time-lapse embryo imaging systems. Of all the embryology technologies 
used in fertility labs, time-lapse embryo imaging is one of the few that is branded and 
directly marketed to patients (Pottage, 2018). The specific software and algorithms 
developed on the basis of the data-generativity of previous embryo populations have 
moreover become products in their own right that are integral to the knowledge 
production and commercialisation strategies in data-driven embryo selection.   
 The datafication of embryo selection converts numerous variables of embryo 
development into quantified data and this phenomenon enables the emergence of new 
reproductive bioeconomies of data sharing between different actors and institutions in 
the fertility sector. In the field of critical data studies, concerns have been raised about 
the “big data divide,” or the “exacerbation of power imbalances in the digital era 
                                                             
5 See Franklin (2013) for a discussion of the “retooling” of reproductive substance in processes of 
“bioindustrialization” (p. 64).  
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resulting from the differential access to data.” Critical reflection on datafication, it is 
suggested, requires considering “the asymmetric relationship between those who 
collect, store, and mine large quantities of data, and those whom data collection 
targets” (Andrejevic, 2014, p. 1673).  
 When IVF cycles become data-generating, different organisations in the 
fertility sector become data-rich in new ways. When using these technologies, the 
fertility clinic takes up a new role of gathering sizeable data sets on developing 
embryos in routine clinical practice and, in some cases, using these to develop in-house 
algorithms. While many clinics have R&D activities, the ongoing data collection at the 
scale that time-lapse systems introduce is unprecedented, as is the introduction of 
algorithmic products to render this data legible. Time-lapse system producers, likewise, 
are gaining access to uniquely large, privately-held data sets about embryo 
development. For example, Vitrolife, producer of the popular EmbryoScope system, 
has access to embryo development profiles and implantation outcomes from over 
30.000 embryos. Embryologists and IVF clinics worldwide have contributed to this 
data set since 2009, thus reportedly creating “the world’s largest database of embryo 
development with known clinical outcome” (Montag, 2015; Vitrolife, 2015a). 
Emerging from a market-driven context, time-lapse embryo imaging systems are thus 
instrumental in the creation of asymmetric relations of private reproductive data 
ownership, diverging significantly from a public health-approach to open data sharing 
that characterised the early history of IVF in the 1970s and 1980s.  
 Rather than inherently valuable, these large-scale data sets extracted from 
developing embryos only acquire value when “data are collated, curated, interpreted 
and otherwise acted upon” (Lezaun, 2013, p. 481). This work of rendering embryo data 
valuable in both reproductive and monetary terms is one of the new forms of labour 
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emerging with datafication that becomes visible through the marketisation of 
algorithmic software for embryo selection. CAREfertility, the UK’s largest fertility 
group, for example, has developed its own proprietary algorithms for embryo selection 
using the Embryoscope. Beyond the potential for improving reproductive outcomes in 
their reproductive cycles, this process itself has become part of its communication to 
patients:  
 
Our scientists are world-leaders in time-lapse technology, and our CAREmaps 
technique is really highly developed; we’ve innovated models that can help us 
choose the best embryo more reliably, allowing us to see whether each has a 
low, medium, or high chance of success. (CAREfertility, 2018)  
 
Rather than only promoting time-lapse embryo imaging itself, the CARE website 
specifically markets its proprietary CAREmaps (morphokinetic algorithms to predict 
success) as the key to IVF success. The datafication of embryo selection thus creates 
novel algorithmic products, which reflect both the new forms of bioinformatical labour 
in the fertility clinic and new forms of value production both through the branding of 
technological innovation and a promise of increased IVF success that comes with an 
additional price tag.  
 At the level of the producer, the labour of collecting and instrumentalising 
embryo data likewise yields software products. Vitrolife’s “largest database” of known 
implantation data (KID) is translated into a valuable asset through its KIDScore tool. 
Along with Vitrolife’s EmbryoScope, clinics can purchase this software package, 
which consists of algorithms that measure the “implantation potential” of the embryos 
in the incubator and provides a “morphokinetic score” between 1 – 5 to embryologists, 
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who can then “select the embryos ranked high with better chances of implanting and 
becoming a child” (Vitrolife, 2015b). The rival system Eeva similarly is coupled with 
the Xtend Algorithm software package, which was developed on the basis of multi-
centre reference data on file at producer Progyny (Merck, 2015). KIDScore and Xtend 
Algorithm assign scores to the embryos to indicate which is more likely to survive. 
Given that these algorithmic tools rely on large sets of “known implantation data,” this 
practice newly aligns the generation of biodata with the generation of biocapital. Social 
scientist Linda Hogle argues that a “tidal wave of efforts to extract value from health 
data has accompanied the big data phenomena, leading to considerable investments by 
pharmaceutical, medical device and health risk management companies”—and, in this 
case, leading to algorithmic products in their own right (2016, p. 386).  
The development of Vitrolife’s and Merck’s algorithmic products relies on the 
presence of existing networks of data connectivities between pharmaceutical, 
biotechnological and fertility companies, given that KIDScore and Xtend were 
developed on the basis of data sets sourced from IVF clinics across the world. The 
(contested) claim that such networked embryo data collection is feasible with these 
time-lapse systems is itself a key element in the marketisation of these algorithmic 
products. After all, their selling point is not simply the promise of improved pregnancy 
rates, but an improved workflow in the lab. Vitrolife emphasises that KIDScore is easy 
to use and requires annotation of only a limited number of variables, which its 
predictive analytics method anticipates. It thereby enables a “high level of consistency 
in embryo scoring in your clinic” (Vitrolife, 2015b). Echoing Jasanoff’s (2017) “view 
from nowhere” regime of sight, this discursive framing of the software points to “an 
overarching principle of interchangeability” underlying the promise of datafication in 
IVF, which applies not only to intra-clinic, but also inter-clinic variability (Lezaun, 
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2013, p. 481). It is this principle that motivates the claim that “KIDScore is universal 
to all clinics and can be used immediately without acquiring your own data first” 
(Vitrolife, 2015b). The upholding of a model of universality and interchangeable 
standardisation is both a key driver and an effect of the datafication of embryo 
selection. Similarly, it is part of a marketing strategy to extend automated embryo 
selection to more clinics, while being in and of itself a condition of emergence for the 
networked reproductive bioeconomies of data sharing and data ownership emerging 
with data-driven IVF. 
As a result, the datafication of embryo selection entails at once the clinical 
introduction of integrated apparatuses for reproductive data generation, the creation of 
connected networks of data sharing, and the production of biocapital out of biodata by 
means of algorithmisation—all of which combine in a system that is marketed directly 
to patients and fertility clinics. The large-scale redistributions of embryo data between 
fertility companies that produce and use time-lapse embryo imaging not only create 
new forms of value, but also reorder institutional relationships as lines between 
research and clinical practices are blurred. What is at stake in these developments is 
that data asymmetries between clinical, pharmaceutical and biotechnological 
organisations reflect and reconfigure the power dynamics in the fertility sector, which I 
will discuss in the next section.  
 
Consolidation and Reproductive Data Infrastructures 
 
The datafication of reproduction is not only transformative in its own right, it is but 
also indicative of how the broader IVF market is being reshaped. The growing 
popularity of time-lapse embryo imaging is situated within an expanding, and 
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increasingly consolidating, fertility sector. The move towards consolidation is manifest 
in the merging of fertility clinics into larger chains, the growing influence of online 
platforms in organising fertility care and the portfolio expansion of pharmaceutical and 
biotechnological companies to include a wider range of fertility products and 
incorporate each step of the fertility journey. The institutional genealogy of time-lapse 
embryo imaging gives insight into, and emerges from, these consolidating 
developments in the global fertility industry.  
 
Consolidating Fertility Groups: Mergers and Acquisitions 
As the global fertility market is growing steadily and is estimated to exceed $21 billion 
by 2020, fertility clinics are increasingly merging into larger chains (Maida, 2016). 
Trends of reproduction later in life, greater awareness and acceptance of fertility 
treatments, increasing privatisation in the UK and increasing insurance coverage in the 
US have been suggested as drivers in this expansion (De Martino and Shapiro, 2017; 
Williams et al., 2017). Whereas new freezing technologies (e.g. egg freezing) preserve 
reproductive potential and expand IVF’s target group with fertile women, new data 
technologies predict reproductive potential and expand the IVF cycle with additional 
treatments (add-ons such as time-lapse embryo imaging). 
 The growth in the sector has been characterised by an ongoing “merger and 
acquisition cycle” as large fertility groups expand their international reach. For 
example, Australian market leader Virtus Health, the world’s first publically listed 
fertility business, operates 46 IVF clinics, after having completed four acquisitions in 
2016-2017 and expanding to Ireland, Denmark and Singapore. Likewise, Abu Dhabi-
based NMC Health acquired both EUVITRO in Spain in 2015 ($162 million) and 
Fakih IVF Group in the United Arab Emirates ($207 million) (Williams et al., 2017). 
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In the UK, CARE Fertility is the largest provider of IVF and has a steadily expanding 
chain of fertility clinics across the country and in Ireland (CHR, 2015). The 2017 
merger of Spanish IVI and US RMNAJ has created the world’s largest fertility group, 
reaching around €300m revenue (Pedrós and González, 2017).  
The datafication of reproduction is situated within these consolidating 
developments in the fertility sector. Given the significant price tag of time-lapse 
embryo imaging systems, transitioning to this data-driven method of embryo selection 
is more feasible for larger clinics. Aided by economies of scale, larger, consolidated 
clinics are typically early adopters of these high-investment systems. For example, 
abovementioned Fakih IVF announces on its homepage that it was the first to introduce 
the EmbryoScope in the AUE. As Carbone and Madeira (2016, p. 112) report, the high 
cost of lab equipment is frequently mitigated through group discounts if they are 
purchased by a larger fertility organisation. Likewise, CAREfertility (2018), the largest 
UK fertility group, writes in a large header on its website that they “were the first UK 
clinic to introduce time-lapse embryo imaging.” Promoting these technologies to 
(potential) patients and the wider public, CAREfertility was at the centre of high-
profile media exposure of time-lapse embryo imaging, which included televised BBC 
news reports on purportedly the “biggest breakthrough in IVF in 25 years” (Walsh, 
2013b).  
This association between consolidation and high-investment innovations gains 
another dimension in the context of datafication. Because time-lapse imaging generates 
data streams with each IVF cycle, larger centres with more annual cycles have the 
benefit of gaining larger data sets on embryo development. Depending on whether this 
data is thought be clinic-specific or sufficiently standardised to be comparable among 
different branches, these data sets can attain biovalue as a means to do research and 
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develop algorithms for embryo selection derived from in-house IVF cycles.  
By rendering the IVF cycle both data-driven and data-generative, time-lapse 
embryo imaging introduces an infrastructural change in the organisation of assisted 
reproduction. Beyond adding another “add-on” to an increasingly wide array of 
treatment options for IVF patients, the server-connected time-lapse imaging systems 
establish a wider reproductive data infrastructure to facilitate embryo selection in 
which the machines function as generative nodes. No longer confined within the walls 
of the IVF lab, embryo selection becomes a process that is differently dispersed across 
time and space as collected embryo data may be shared with patients, embryologists or 
manufacturers. The practices of data sharing across these new infrastructures differ as 
some clinics only use a local area network (LAN) and keep their data in-house, while 
others share and receive embryo data with other organisations. The new pathways for 
(automated) embryo data sharing that emerge with the introduction of time-lapse 
embryo imaging enable new forms of connectivity between actors in the fertility 
industry—whether through the live-streaming embryo videos from the incubator to the 
intended parents’ iPad or through downloads of updated parameters for embryo 
selection from the manufacturer into the local time-lapse system. Even if not all 
pathways for data sharing built-in to the system are necessarily in use, the introduction 
of time-lapse systems facilitates automated embryo data exchanges between the 
manufacturer, the patient and the incubator in the IVF lab. The resultant key shift is 
that the direction and scope of embryo data flows are constrained by the clinic’s 
decision-making rather than primarily logistic in nature.  
The spatial dispersal of the embryo selection process enabled by time-lapse 
systems particularly suits the spatial dispersal of consolidated fertility companies that 
expand their geographical reach through mergers and acquisitions. The connectivity 
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built-in to the time-lapse systems offers a means of bridging the distances between 
clinics within a single group by streamlining embryo selection protocols and practices 
and by sharing embryo data to build proprietary data sets. The alignment of in-house 
reproductive data infrastructures and the organisational model of consolidated fertility 
companies may thus widen the gap associated with data and financial asymmetries 
between smaller and larger organisations. In the case of time-lapse embryo imaging, 
consolidation and datafication thus appear to function as mutually-reinforcing 
conditions of co-emergence. Larger clinics facilitate the introduction of the apparatuses 
while the connected and automated method materialised in the machine facilitates 
coordinating clinical processes across different labs and clinics.  
 
Platformising Fertility: Consolidating Across Technological Domains  
The institutional genealogy of time-lapse embryo imaging highlights a wider trend of  
“platformisation” (Van Dijck et al., 2016). Here the online fertility platform, rather 
than the fertility clinic, comes to function as a key organising principle of fertility care. 
A case in point is the Eeva test, which was first produced by Auxogyn, a 
biotechnological company which attained exclusive licencing for the technology 
through the abovementioned Stanford patent. In 2014, Auxogyn merged with 
FertilityAuthority, a “patient-matching technology platform” and self-reportedly the 
world’s largest fertility web portal with 1 million monthly visitors, which had itself 
acquired the leading global FertileThoughts.com social network in 2010 (Fertility 
Authority, 2015). The resulting Progyny, Eeva’s producer and self-described “digital 
health company,” is organised around the online platform as the point of access to a 
network of clinics and a variety of in-house services, including IVF Advantage 
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(fertility loans), Eggbanxx (egg freezing) and Progyny corporate fertility insurance.6 In 
this platformised approach to fertility care, Progyny’s mission is to be “the go-to 
source for all fertility solutions” (Mack, 2016). It thus brings digital health to assisted 
reproduction by combining investments in a data-driven embryo selection technology 
with a digital reproductive health platform that integrates branded biotechnological, 
clinical, financing, insurance and communication services.  
By integrating previously separate fertility services under its online umbrella, 
the company disrupts the conventional clinic-based delivery of fertility care and 
introduces new treatment rationales for reproductive decision-making through its 
online and offline channels in line with its diverse portfolio. For example, the Eeva test 
had its own website, was the subject of expert advice on the FertilityAuthority platform 
and was introduced in moderator-initiated discussions on the FertileThoughts forum. It 
was also included in Progyny’s corporate fertility benefit package, which covered 
treatment plans for employees that “start with egg or embryo freezing, include testing 
of the embryo to reduce miscarriage, and include a single embryo transfer (SET) that 
when coupled with the healthiest embryo, result in the fastest track to success” 
(McCarthy, 2016). The Eeva test is thus embedded in a broader reframing of the 
reproductive process through Progyny’s mission to “combine service, science and data 
to optimize the clinical outcomes of fertility treatments” (Progyny, 2017). Egg freezing 
is included as a means to avoid the risk of future involuntary childlessness and 
optimise a potential IVF procedure with higher quality eggs. The inclusion of data-
driven embryo selection approaches is rationalised as a condition for successful single 
embryo transfer to avoid multiple births.  
Progyny’s vision thus promotes a treatment rationale that expands the scope of 
                                                             
6 With a network of over 455 clinics and a focus on servicing Fortune 500 companies, Progyny is 
currently the leading fertility benefits provider in the US. 
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IVF both by encouraging younger fertile women to pre-emptively undergo infertility 
treatment and by increasing the number of treatment steps in each cycle to optimise 
clinical outcomes. This reframing of the reproductive process entails both the 
financialisation of reproductive risk and its proposed mitigation through a highly-
technologised and revenue-generating set of treatments. Progyny’s pre-emptive 
treatment rationale of avoiding reproductive and financial risk thus normalises a high-
tech IVF treatment course for a larger group of potential candidates, which may be 
reached through both online platforms and their employers’ HR departments, and 
unambiguously represents reproductive and data technologies as the best risk-
mitigating strategies to “ensure that anyone who wants to have a child, can have one” 
(Progyny 2017).  
 
Consolidating the Whole IVF Journey  
The increasing prevalence of time-lapse embryo imaging also intersects with a 
consolidating trend of vertical integration of the fertility industry, as those companies 
producing reproductive data technologies expand their portfolios to cover the “entire 
IVF journey.” All of the major companies producing time-lapse imaging apparatuses—
Genea, Progyny, Merck and Vitrolife—explicitly voice this ambition in their 
marketing and investment materials. Vitrolife’s presents its various products—lab 
instruments, culture media, imaging technologies, etc—as an integrated portfolio to 
“maximise success every step of the way” (Vitrolife, 2018c). Likewise, upon 
introducing its Geri time-lapse system, Merck announced that “With an Extended 
Fertility Technologies Portfolio Merck now Covers all IVF Steps” (Merck, 2016).  
After various acquisitions and alliances since 2013, Merck and Vitrolife, a 
pharmaceutical and biotechnological company, currently distribute all four major time-
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lapse embryo imaging systems. In line with the ambition to cover every stage of the 
IVF process, the “add-on” technology of time-lapse embryo imaging provides an 
opportunity to expand the treatment steps per cycle and popularise new forms of 
standardisation within assisted reproduction.  
Vitrolife produces both the Primovision system and, after acquisition of its 
former producer Fertilitech in 2014, the Embryoscope. Vitrolife specialises in IVF 
culture media and disposables, such as pipettes and dishes. The inclusion of time-lapse 
embryo imaging in their business model has proven to be highly successful and sales 
of these machines have increased each quarter since 2014 (Vitrolife, 2018a). They 
estimate that 10% of IVF centres in the world and over half of UK clinics use their 
time-lapse embryo imaging machines (Vitrolife, 2017, p. 3). These high figures 
indicate that a growing number of patients and professionals will encounter the option 
to include these machines as part of their IVF cycles. As the company seeks to cover 
every step of the reproductive process, the IVF cycle overlaps with the “value chain” 
of Vitrolife products (Axelsson, 2016, p. 6). The added step of data-driven embryo-
selection technology affirms the wider trend of the “value per cycle increasing through 
better technologies,” an effect that is intensified by a related trend of more cycles 
following a single “oocyte pick-up” (Axelsson, 2016, p. 16). Addressing investors, the 
company specifically makes the business case for time-lapse embryo imaging as a 
high-tech marketing tool and as a means to increase income per cycle, given that the 
cost (€50 – €200) is significantly lower than the standard selling price (€400 – €1000) 
per treatment (Ramsing, 2016, p. 11). In considering digital reproductive health, it is 
important to highlight that the emergence of new digital subjectivities, knowledges and 
networks is situated in a rapidly growing global fertility sector; its rationality of 
expansion is a key driver of the increasing datafication of reproduction.  
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Another major player in the fertility sector is Merck, a multinational 
pharmaceutical company with approximately 50.000 employees in 70 countries, which 
is a leading distributor of the fertility drugs used in IVF cycles. Recently biosimilars to 
Merck’s major fertility drugs for IVF ovarian stimulation have been introduced 
(Allahbadia and Allahbadia, 2016; Winstel et al., 2017). At this time, the company is 
also expanding its portfolio to include time-lapse embryo imaging by partnering with 
both Genea, which produces the Geri system, and abovementioned Progyny, which 
produces the Eeva test. Investments in these data-driven systems are part of its broader 
strategy to “cover all IVF steps” and develop “from a drug provider to an integrated 
fertility partner” (Wenzel, 2017). Alongside this ambition, a key goal of the Global 
Fertility Alliance, of which Merck is a founding member, is to promote 
“standardization and automation in In Vitro Fertilisation (IVF) clinics” (GFA, 2018). 
Investments in automated and standardised embryo selection through data-driven 
technologies that materialise these principles align with this wider goal.  
 The blurring of the lines between clinical and capitalist rationales in these 
global reproductive bioeconomies is foundational to the datafication of reproduction 
and raises concerns about the implications of the concomitant corporatisation of IVF. 
The valuation of time-lapse embryo imaging follows not only from the 
commodification of add-on treatments, algorithms and selection apparatuses, but it is 
also a materialisation of an expansive drive within global IVF enabled by 
standardisation, automation and data-generativity. Alongside a critique that IVF 
becomes overly shaped by corporate interests is a concern that the specific 
corporatisation of data-driven embryo selection may both enlist fertility clinics and 
patients in treatment rationales that require even more investment per cycle and create 
technological lock-ins that make clinics beholden to particular platforms, thereby 
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potentially intensifying data and financial asymmetries within assisted reproduction 
(Kitchin, 2014, pp. 181–182).  
 
Conclusion  
The data-driven selection of embryos with time-lapse embryo imaging has primarily 
been discussed in terms of its clinical efficacy, but its introduction reflects and 
reconfigures a range of practices within the contemporary fertility sector. As Sarah 
Franklin (2013) has argued for IVF, time-lapse embryo imaging provides a lens onto 
the reconceptualisation and recommodification of prenatal life when data technologies 
and reproductive technologies meet. 
 The datafication of embryo selection shifts clinical practice by introducing a 
new treatment option that renders embryo viability visible and calculable by means of 
an algorithmically-assisted way of seeing. With the introduction of this “in silico 
vision” in the embryological workflow, IVF cycles do not only produce babies, but 
also sizable data sets on embryo development. As data flows of embryos are shared—
or withheld—between embryologists, corporations and patients, embryo selection 
becomes a more networked and commercialised activity in which different actors have 
a stake. 
The establishment of emergent reproductive data infrastructures through the 
introduction of growing numbers of time-lapse embryo imaging systems raises 
questions about who may access and who can claim ownership of this embryo data. 
The patenting of this process highlights how the embryos’ data-generativity may be 
repurposed as a method for selection, how observable characteristics of embryo 
development are transformed into private property, and how the development of 
bioinnovations is increasingly reliant on funding from for-profit partners. The sizable 
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data sets about embryogenesis collected through this system provide the basis for the 
creation of new algorithmic products for embryo selection by biotechnological and 
pharmaceutical companies. This process of turning biodata into biocapital relies on 
reproductive data infrastructures, through which new data and power asymmetries 
between different actors in the fertility sector are construed and consolidated.  
What is remarkable about the commercialisation of time-lapse technologies is 
the way in which strategies of patenting, direct-to-consumer branding, privately-held 
data accumulation, its algorithmisation into selection tools and ownership of the whole 
IVF supply chain are combined into a total system for data-driven embryo selection. 
This multipronged move towards datafication, and the concomitant promise of 
automation, standardisation and data/capital accumulation in a more networked mode 
of embryo selection, both reflects and reinforces a consolidating trend in the fertility 
sector—characterised by mergers resulting in larger fertility chains, online platforms 
adopting a key role in the organisation of fertility care and the portfolio expansion of 
pharmaceutical and biotechnological companies to cover each step of the IVF cycle.  
In the context of this Special Issue I therefore want to emphasise that the 
emergence of new digital subjectivities, knowledges and networks in digital 
reproductive health are situated in a rapidly growing global fertility sector; its 
rationality of expansion is a key driver of the datafication of reproduction. What is at 
stake, then, in the enmeshed forms of biocapital and biodata that emerge with the 
datafication of (reproductive) health care is not only the increase or decrease of 
pregnancy rates, but numerous conceptual, epistemological and institutional shifts that 
lie at the foundation of both contemporary technologized reproduction and the future 
reconfigurations of the relation between biomedicine and society. It is, in other words, 
crucial to understand data-driven IVF as not a peripheral phenomenon, but as a 
29 
 
harbinger of how power relations between networks of social and corporate actors can 
be built-in to the institutional infrastructures that deliver digital health. 
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